|
Synonyms
|
AGE-R3, CBP35, GAL3, L29, LGALS3, Mac-2
|
|
Species
|
Human
|
|
Accession
|
P17931
|
|
GeneID
|
3958
|
|
Source
|
Escherichia coli.
|
|
Molecular Weight
|
重组人半乳凝素-3蛋白Approximately 26.0 kDa, a single non-glycosylated polypeptide chain containing 249 amino acids.
|
|
Quantity
|
10µg/50µg/1000µg
|
|
AA Sequence
|
ADNFSLHDAL SGSGNPNPQG WPGAWGNQPA GAGGYPGASY PGAYPGQAPP GAYPGQAPPG AYPGAPGAYP GAPAPGVYPG PPSGPGAYPS SGQPSATGAY PATGPYGAPA GPLIVPYNLP LPGGVVPRML ITILGTVKPN ANRIALDFQR GNDVAFHFNP RFNENNRRVI VCNTKLDNNW GREERQSVFP FESGKPFKIQ VLVEPDHFKV AVNDAHLLQY NHRVKKLNEI SKLGISGDID LTSASYTMI
|
|
Purity
|
重组人半乳凝素-3蛋白> 98 % by SDS-PAGE and HPLC analyses.
|
|
Biological Activity
|
Fully biologically active when compared to standard. The ED50 as determined by its ability to agglutinate human red blood cells is less than 10 μg/ml.
|
|
Physical Appearance
|
Sterile Filtered White lyophilized (freeze-dried) powder.
|
|
Formulation
|
Lyophilized from a 0.2 µm filtered solution in 1 × PBS, pH 7.4, 3mM DTT.
|
|
Endotoxin
|
Less than 0.1 EU/µg of rHuGalectin-3 as determined by LAL method.
|
|
Reconstitution
|
重组人半乳凝素-3蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
|
|
Storage
|
This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.
|
|
重组人半乳凝素-3蛋白
|
|
|
SDS-PAGE
|
|
|
Reference
|
1. J Dumic, S Dabelic, M Flogel. 2006. Biochim Biophys Acta, 1760: 616-35.
2. J Raimond, DB Zimonjic, C Mignon, et al. 1997. Mamm Genome, 8: 706-7.
3. DN Cooper. 2002. Biochim Biophys Acta, 1572: 209-31.
4. NC HendersonandT Sethi. 2009. Immunol Rev, 230: 160-71.
5. YP Yan, BT Lang, R Vemuganti, et al. 2009. Brain Res, 1288: 116-24.
6. YH Lin, LY Lin, YW Wu, et al. 2009. Clin Chim Acta, 409: 96-9.
|
|
Background
|
Human Galectin-3 also named AGE-R3, CBP35, GAL3, L29, LGALS3, Mac-2, is belonging to the galectins family and it is encoded by a single gene, LGALS3, located on chromosome 14, locus q21–q22. It is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. Galectin-3 is approximately 30 kDa and, like all galectins, contains a carbohydrate-recognition-binding domain (CRD) of about 130 amino acids that enable the specific binding of β-galactosides. Given Galectin-3’s broad biological functionality, it has been demonstrated to be involved in cancer, inflammation and fibrosis, heart disease, and stroke. Studies have also shown that the expression of galectin-3 is implicated in a variety of processes associated with heart failure, including myofibroblast proliferation, fibrogenesis, tissue repair, inflammation, and Ventricular remodeling. Human Galectin-3 shares 79% amino acid sequence identity with rat and mouse Galectin-3, respectively.
|
